 |
|
Antipsychotic Drug Effects on Brain Morphology in First-Episode Psychosis
Jeffrey A. Lieberman, MD;
Gary D. Tollefson, MD, PhD;
Cecil Charles, PhD;
Robert Zipursky, MD;
Tonmoy Sharma, MD;
Rene S. Kahn, MD, PhD;
Richard S. E. Keefe, PhD;
Alan I. Green, MD;
Raquel E. Gur, MD, PhD;
Joseph McEvoy, MD;
Diana Perkins, MD, MPH;
Robert M. Hamer, PhD;
Hongbin Gu, PhD;
Mauricio Tohen, MD, DrPH; for the HGDH Study Group
Arch Gen Psychiatry. 2005;62:361-370.
Background Pathomorphologic brain changes occurring as early as first-episode schizophrenia have been extensively described. Longitudinal studies have demonstrated that these changes may be progressive and associated with clinical outcome. This raises the possibility that antipsychotics might alter such pathomorphologic progression in early-stage schizophrenia.
Objective To test a priori hypotheses that olanzapine-treated patients have less change over time in whole brain gray matter volumes and lateral ventricle volumes than haloperidol-treated patients and that gray matter and lateral ventricle volume changes are associated with changes in psychopathology and neurocognition.
Design Longitudinal, randomized, controlled, multisite, double-blind study. Patients treated and followed up for up to 104 weeks. Neurocognitive and magnetic resonance imaging (MRI) assessments performed at weeks 0 (baseline), 12, 24, 52, and 104. Mixed-models analyses with time-dependent covariates evaluated treatment effects on MRI end points and explored relationships between MRI, psychopathologic, and neurocognitive outcomes.
Setting Fourteen academic medical centers (United States, 11; Canada, 1; Netherlands, 1; England, 1).
Participants Patients with first-episode psychosis (DSM-IV) and healthy volunteers.
Interventions Random allocation to a conventional antipsychotic, haloperidol (2-20 mg/d), or an atypical antipsychotic, olanzapine (5-20 mg/d).
Main Outcome Measures Brain volume changes assessed by MRI.
Results Of 263 randomized patients, 161 had baseline and at least 1 postbaseline MRI evaluation. Haloperidol-treated patients exhibited significant decreases in gray matter volume, whereas olanzapine-treated patients did not. A matched sample of healthy volunteers (n = 58) examined contemporaneously showed no change in gray matter volume.
Conclusions Patients with first-episode psychosis exhibited a significant between-treatment difference in MRI volume changes. Haloperidol was associated with significant reductions in gray matter volume, whereas olanzapine was not. Post hoc analyses suggested that treatment effects on brain volume and psychopathology of schizophrenia may be associated. The differential treatment effects on brain morphology could be due to haloperidol-associated toxicity or greater therapeutic effects of olanzapine.
Author Affiliations: Departments of Psychiatry, University of North Carolina School of Medicine, Chapel Hill (Drs Lieberman, Perkins, Hamer, and Gu); University of Utrecht Medical School, Utrecht, the Netherlands (Dr Kahn); Duke University School of Medicine, Durham, NC (Drs Keefe and McEvoy); Dartmouth Medical School, Hanover, NH (Dr Green); University of Pennsylvania School of Medicine, Philadelphia (Dr Gur); Harvard Medical School, Boston, Mass (Dr Tohen); Lilly Research Laboratories, Indianapolis, Ind (Drs Tollefson and Tohen); Department of Radiology, Duke University School of Medicine (Dr Charles); University of Toronto Faculty of Medicine, Toronto, Ontario (Dr Zipursky); and Clinical Neuroscience Research Centre, Kent, England (Dr Sharma). Dr Lieberman is now with the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, and New York State Psychiatric Institute, New York.
RELATED LETTER
Is Olanzapine a Brain-Sparing Medication?
Ridha Joober, Norbert Schmitz, Ashok Malla, Sarojini Sengupta, and Sherif Karma
Arch Gen Psychiatry. 2006;63(11):1292.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Science and Recovery in Schizophrenia
Lieberman et al.
Psychiatr. Serv. 2008;59:487-496.
ABSTRACT
| FULL TEXT
Excessive Brain Volume Loss Over Time in Cannabis-Using First-Episode Schizophrenia Patients
Rais et al.
Am. J. Psychiatry 2008;165:490-496.
ABSTRACT
| FULL TEXT
Progressive Brain Changes in Schizophrenia
Arango and Kahn
Schizophr Bull 2008;34:310-311.
FULL TEXT
Longitudinal Brain Changes in Early-Onset Psychosis
Arango et al.
Schizophr Bull 2008;34:341-353.
ABSTRACT
| FULL TEXT
Randomized Controlled Trials for Schizophrenia: Study Designs Targeted to Distinct Goals
Stroup and Geddes
Schizophr Bull 2008;34:266-274.
ABSTRACT
| FULL TEXT
The Concept of Progressive Brain Change in Schizophrenia: Implications for Understanding Schizophrenia
DeLisi
Schizophr Bull 2008;34:312-321.
ABSTRACT
| FULL TEXT
What Happens After the First Episode? A Review of Progressive Brain Changes in Chronically Ill Patients With Schizophrenia
Hulshoff Pol and Kahn
Schizophr Bull 2008;34:354-366.
ABSTRACT
| FULL TEXT
Cerebral Disconnectivity: An Early Event in Schizophrenia
Begre and Koenig
Neuroscientist 2008;14:19-45.
ABSTRACT
Disturbed Structural Connectivity in Schizophrenia Primary Factor in Pathology or Epiphenomenon?
Konrad and Winterer
Schizophr Bull 2008;34:72-92.
ABSTRACT
| FULL TEXT
Association Between Brain-Derived Neurotrophic Factor Val66Met Gene Polymorphism and Progressive Brain Volume Changes in Schizophrenia
Ho et al.
Am. J. Psychiatry 2007;164:1890-1899.
ABSTRACT
| FULL TEXT
Grey matter abnormalities in first-episode schizophrenia and affective psychosis
MORGAN et al.
Br. J. Psychiatry 2007;191:s111-s116.
ABSTRACT
| FULL TEXT
Computational anatomical methods as applied to ageing and dementia
THOMPSON and APOSTOLOVA
Br. J. Radiol. 2007;80:S78-S91.
ABSTRACT
| FULL TEXT
Neuroimaging and other neurobiological indices in schizophrenia: relationship to measurement of functional outcome
Waddington
Br. J. Psychiatry 2007;191:s52-s57.
ABSTRACT
| FULL TEXT
Measuring Brain Volume by MR Imaging: Impact of Measurement Precision and Natural Variation on Sample Size Requirements
Steen et al.
Am. J. Neuroradiol. 2007;28:1119-1125.
ABSTRACT
| FULL TEXT
Progressive and Interrelated Functional and Structural Evidence of Post-Onset Brain Reduction in Schizophrenia
Salisbury et al.
Arch Gen Psychiatry 2007;64:521-529.
ABSTRACT
| FULL TEXT
Managing the acute psychotic episode
Byrne
BMJ 2007;334:686-692.
FULL TEXT
Altered orbitofrontal sulcogyral pattern in schizophrenia
Nakamura et al.
Brain 2007;130:693-707.
ABSTRACT
| FULL TEXT
Middle and Inferior Temporal Gyrus Gray Matter Volume Abnormalities in First-Episode Schizophrenia: An MRI Study
Kuroki et al.
Am. J. Psychiatry 2006;163:2103-2110.
ABSTRACT
| FULL TEXT
Is olanzapine a brain-sparing medication?
Joober et al.
Arch Gen Psychiatry 2006;63:1292-1292.
FULL TEXT
Smaller neocortical gray matter and larger sulcal cerebrospinal fluid volumes in neuroleptic-naive women with schizotypal personality disorder.
Koo et al.
Arch Gen Psychiatry 2006;63:1090-1100.
ABSTRACT
| FULL TEXT
Brain volume changes in the first year of illness and 5-year outcome of schizophrenia
CAHN et al.
Br. J. Psychiatry 2006;189:381-382.
ABSTRACT
| FULL TEXT
Prediction of functional outcome 18 months after a first psychotic episode: a proton magnetic resonance spectroscopy study.
Wood et al.
Arch Gen Psychiatry 2006;63:969-976.
ABSTRACT
| FULL TEXT
Mapping Brain Maturation
Toga et al.
Focus 2006;4:378.
ABSTRACT
| FULL TEXT
The Choice of Drugs for Schizophrenia
Davis
NEJM 2006;354:518-520.
FULL TEXT
Hippocampal and Amygdala Volumes According to Psychosis Stage and Diagnosis: A Magnetic Resonance Imaging Study of Chronic Schizophrenia, First-Episode Psychosis, and Ultra-High-Risk Individuals
Velakoulis et al.
Arch Gen Psychiatry 2006;63:139-149.
ABSTRACT
| FULL TEXT
The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia
Ohnishi et al.
Brain 2006;129:399-410.
ABSTRACT
| FULL TEXT
Structural Brain Imaging Evidence for Multiple Pathological Processes at Different Stages of Brain Development in Schizophrenia
Pantelis et al.
Schizophr Bull 2005;31:672-696.
ABSTRACT
| FULL TEXT
Can Meds Halt Schizophrenia's Gray-Matter Decline?
Rosack
Psychiatr. News 2005;40:38-38.
FULL TEXT
|
